Topical treatment of ulcerative colitis

It is clear that the therapeutic options available for the treatment of ulcerative proctosigmoiditis have increased over the last few years and in the future additional therapies will be available. Therapy will have to be individualized. Studies to date have generally failed to confirm the superiority of one form of treatment over another, although there is some evidence that high-dose 5-ASA enemas are superior to hydrocortisone enemas. Patients who fail to respond to one form of therapy may respond to another therapeutic modality. Continued evaluation of topical therapies provides not only an opportunity to improve the treatment prospects for patients but also allows for examination of potential mechanisms of action of therapeutically active compounds. Future research directions should also include assessment of combination therapy, the more widespread use of suppositories, and strategies to encourage patient compliance. Larger multicenter trials are needed to assess the effectiveness of some of the newer compounds. The role of topical therapy for patients with Crohn's disease confined to the left colon requires evaluation.